Skip to main content
HANDOK Inc. logo

HANDOK Inc. — Investor Relations & Filings

Ticker · 002390 ISIN · KR7002390003 KO Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2026-05-19 Director's Dealing
Country KR South Korea
Listing KO 002390

About HANDOK Inc.

https://www.handok.co.kr/en/

Handok Inc. is a total healthcare company that develops, manufactures, and distributes a comprehensive range of healthcare solutions. Its portfolio includes prescription drugs, general medicine, medical devices, and in-vitro diagnostics. The company's core business focuses on therapeutic areas such as diabetes, cardiovascular and musculoskeletal diseases, and psychoneurotic disorders, in addition to human vaccines. Positioning itself as a "Health Innovator," Handok provides products and services aimed at prevention, diagnosis, and health management. The company collaborates with global enterprises and manages the entire value chain from sourcing and development to commercialization.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 98% confidence The document is a regulatory disclosure filed with the Korean Financial Services Commission and Korea Exchange by an executive, detailing the insider’s ownership of specific securities before and after transactions, with quantities, percentages, and transaction dates. This matches an insider transaction/Director’s Dealing report category.
2026-05-19 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 85% confidence The document is a Korean regulatory filing titled “주식매수선택권 부여에 관한 신고” (Notification of Granting Stock Options), including a correction (“정정신고”) of the original notice. It details the number of options, participants, exercise conditions, and all material terms of a share‐based issuance. This is not an earnings release, management commentary, or audit report but an announcement of a capital change event (grant of stock options). Under our taxonomy, stock option grants fall under Share Issue/Capital Change (SHA).
2026-05-14 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 85% confidence The document is a regulatory “신고” (report) filed with the Financial Supervisory Commission and Korea Exchange concerning the grant (and correction to a prior grant report) of stock options (주식매수선택권 부여). It details the number of options, recipients, exercise conditions, and reflects an adjustment to a previously submitted grant. This represents a capital change event (issuance of share options) rather than an operational or financial statement. Accordingly, it falls under the Share Issue/Capital Change category (SHA).
2026-05-14 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 80% confidence The document is a company notice (“공시”) to the financial regulator and stock exchange regarding the grant and correction of stock options (주식매수선택권 부여) to directors and employees. It is not a full financial report or earnings release, but an announcement of a capital change (issuance of share options). The best matching category is "Share Issue/Capital Change" (SHA).
2026-05-14 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is a detailed 분기보고서 (“quarterly report”) covering the period January 1 – March 31 2026 with comprehensive financial statements, segment data, operational metrics, risk disclosures, and other interim‐period information. It is not simply an announcement or certification and clearly constitutes an actual interim/quarterly financial report. Therefore, it fits the category for Interim / Quarterly Report (IR). Q1 2026
2026-05-14 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 95% confidence The document is titled as a preliminary or provisional business performance announcement (영업(잠정)실적(공정공시)) for the first quarter of 2026, with financial figures such as sales, operating profit, and net income presented. It explicitly states that the figures are provisional and subject to change after external auditor review. The document length is short (2095 characters) and it serves as a timely disclosure of quarterly financial results rather than a full interim report with detailed financial statements and analysis. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly financial results with key highlights only. Q1 2026
2026-04-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.